Inflammatory mediators in chronic inflammatory bowel diseases.

Area of Science:

• Immunology
• Gastroenterology
• Cell Biology

Background:

• Inflammatory bowel diseases (IBD), including Crohn's disease and ulcerative colitis, are chronic conditions of unknown origin.
• IBD pathogenesis involves the activation of intestinal mononuclear cells and dysregulated cytokine production.
• Cytokines are critical regulators of immune cell function in the gut.

Purpose of the Study:

• To investigate the role of specific cytokines in the immune response associated with IBD.
• To analyze the balance of pro-inflammatory and anti-inflammatory cytokines in IBD patients.
• To understand the impact of IBD treatments on cytokine synthesis.

Main Methods:

• Analysis of cytokine profiles in patients with IBD.
• Measurement of cytokine synthesis by peripheral blood mononuclear cells (PBMCs).
• Assessment of cytokine production by monocytes/macrophages and lymphocytes.

Main Results:

• Elevated synthesis of interleukin-1 (IL-1), interleukin-6 (IL-6), and tumor necrosis factor alpha (TNF alpha) in IBD patients.
• Decreased synthesis of interleukin-2 (IL-2) and interferon gamma (IFN gamma) observed.
• Increased blood levels and PBMC synthesis of IL-1, IL-6, and TNF alpha, particularly in Crohn's disease.
• Common IBD medications were found to impair monocyte/macrophage cytokine synthesis.

Conclusions:

• Cytokine dysregulation, characterized by increased pro-inflammatory cytokines and decreased certain lymphocyte-derived cytokines, is a key feature of IBD.
• Peripheral immune cells reflect the inflammatory state seen in the gut of IBD patients.
• Therapeutic interventions for IBD may influence cytokine production pathways.